Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.49 |
| ▸ | BRAF | P15056 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347350 | 0.84 | HCRTR2 (0.52) | KDRBRAFABL1POLBGSK3A | |
| SCHEMBL3327606 | 0.80 | ABL1 (0.45) | KDRBRAFMEN1LMNAKMT2A | |
| SCHEMBL10192288 | 0.79 | EPHX2 (0.46) | KDRBRAFMEN1LMNAKMT2A | |
| SCHEMBL3321999 | 0.78 | BRAF (0.51) | KDRBRAFMEN1LMNAKMT2A | |
| SCHEMBL10143875 | 0.76 | POLB (0.52) | MEN1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL3332840 | 0.75 | ABL1 (0.47) | LMNAMAPTNPSR1ABL1POLB | |
| SCHEMBL10191574 | 0.75 | GNRHR (0.39) | KDRBRAFMEN1LMNAKMT2A | |
| SCHEMBL3339751 | 0.73 | ABL1 (0.47) | HTTNPSR1ABL1POLBGSK3A | |
| SCHEMBL3332482 | 0.73 | POLB (0.59) | MEN1LMNAKMT2AMAPTABL1 | |
| SCHEMBL12058718 | 0.72 | POLB (0.60) | ABL1POLBGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653125-B2 | Cyclohexane derivative having NPY Y5 receptor antagonism | SHIONOGI CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | KDR 895/4885BRAF 3058/4885MEN1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.